On November 24, 2025, the FDA approved a supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs). This approval, designated as an efficacy supplement, was granted to Genentech Inc.
Background
Tecentriq Hybreza is a co-formulation of atezolizumab and hyaluronidase-tqjs. This supplemental approval, granted to Genentech Inc., specifically addresses the efficacy of the drug, as classified by the FDA.
What this means
The FDA's approval of this supplemental efficacy application for Tecentriq Hybreza indicates a regulatory confirmation or update regarding the drug's effectiveness. This type of approval reinforces the drug's profile as an efficacious treatment option.
Source
Information regarding the supplemental approval for Tecentriq Hybreza was obtained from the U.S. Food and Drug Administration (FDA). The approval of supplemental application BLA761347 S-4, classified for efficacy, was recorded on November 24, 2025, and is accessible via accessdata.fda.gov.